Aurobindo Pharma has received an approval to raise funds upto $350 million through Issue of Securities. The Board of Directors of the Company at its Meeting held on November 25, 2014 has considered and approved for the same.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
